Skip to search formSkip to main contentSkip to account menu

AS1404

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

vadimezan

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial
Purpose 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) (AS1404) is a novel antitumour agent that selectively disrupts tumour… 
2007
2007
Randomized phase II study of docetaxel with or without DMXAA (AS1404) in hormone-refractory metastatic prostate cancer (HRMPC)
5115 Background: DMXAA (AS1404) is a small-molecule agent that disrupts tumor vasculature. Combination of DMXAA with taxanes… 
2007
2007
Combination of the vascular disrupting agent DMXAA (AS1404) with bevacizumab and paclitaxel produces synergistic antitumor activity in lung cancer xenografts
4642 The anti-VEGF monoclonal antibody, bevacizumab, has been approved for use alongside chemotherapy in colorectal, non-small… 
2007
2007
Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)
SummaryAims: DMXAA (AS1404), a small-molecule vascular disrupting agent that has now completed Phase II clinical trial, induces… 
2007
2007
NF-kappaB-independent induction of endothelial cell apoptosis by the vascular disrupting agent DMXAA.
BACKGROUND DMXAA (5,6-dimethylxanthenone-4-acetic acid; AS1404), a vascular disrupting agent currently in clinical trials… 
2007
2007
Licensing deals morph to acquisitions in seller's market
Pharma's pipeline problems, coupled with the trend toward acquisition, are giving biotechs more leverage in licensing discussions… 
2007
2007
5028 POSTER Update of phase II study of DMXAA (AS1404) combined with carboplatin and paclitaxel in recurrent ovarian cancer
2006
2006
Phase II study of DMXAA combined with carboplatin and paclitaxel in recurrent ovarian cancer.
5032 Background: DMXAA (AS1404) is a small-molecule vascular disrupting agent, which in animal models shows additive or supra… 
2006
2006
Phase Ib/II study of DMXAA combined with carboplatin and paclitaxel in non-small cell lung cancer (NSCLC).
7102 Background: DMXAA (AS1404) is a small-molecule vascular disrupting agent, which in animal models shows additive or supra… 
2005
2005
Targeting Established Tumor Vasculature: A Novel Approach to Cancer Treatment
The selective targeting of established tumor vasculature represents an attractive new anticancer drug strategy, distinct from… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)